Eesti - eesti - Ravimiamet

fresenius kabi polska sp. z o.o. - remifentaniil - süste-/infusioonilahuse kontsentraadi pulber - 5mg 5tk

Eesti - eesti - Ravimiamet

fresenius kabi polska sp. z o.o. - irinotekaan - infusioonilahuse kontsentraat - 20mg 1ml 5ml 1tk; 20mg 1ml 25ml 1tk; 20mg 1ml 15ml 1tk; 20mg 1ml 2ml 1tk

Eesti - eesti - Ravimiamet

fresenius kabi polska sp. z o.o. - paklitakseel - infusioonilahuse kontsentraat - 6mg 1ml 16.7ml 1tk; 6mg 1ml 5ml 5tk; 6mg 1ml 100ml 5tk; 6mg 1ml 50ml 1tk; 6mg 1ml 50ml 5tk; 6mg 1ml 100ml 1tk; 6mg 1ml 5ml 1tk; 6mg 1ml 25ml 1tk

Eesti - eesti - Ravimiamet

fresenius kabi polska sp. z o.o. - oksaliplatiin - infusioonilahuse kontsentraat - 5mg 1ml 40ml 1tk; 5mg 1ml 20ml 1tk; 5mg 1ml 10ml 1tk

Eesti - eesti - Ravimiamet

fresenius kabi polska sp. z o.o. - karboplatiin - infusioonilahuse kontsentraat - 10mg 1ml 60ml 1tk; 10mg 1ml 45ml 1tk; 10mg 1ml 5ml 1tk; 10mg 1ml 15ml 1tk

Eesti - eesti - Ravimiamet

fresenius kabi polska sp. z o.o. - etoposiid - infusioonilahuse kontsentraat - 20mg 1ml 10ml 1tk; 20mg 1ml 5ml 1tk; 20mg 1ml 50ml 1tk

Eesti - eesti - Ravimiamet

fresenius kabi deutschland gmbh - propofool - süste-/infusiooniemulsioon - 10mg 1ml 20ml 10tk; 10mg 1ml 50ml 1tk; 10mg 1ml 20ml 5tk

Eesti - eesti - Ravimiamet

fresenius kabi deutschland gmbh - propofool - süste-/infusiooniemulsioon - 20mg 1ml 50ml 1tk; 20mg 1ml 50ml 15tk; 20mg 1ml 50ml 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - pegfilgrastim - neutropeenia - immunostimulants, , mesilaspere stimuleerivaid faktoreid - neutropeenia ja febriilse neutropeenia esinemissageduse vähendamine ravitud tsütotoksilise kemoteraapia pahaloomulise kasvaja (välja arvatud krooniline müeloidne leukeemia ja müelodüsplastilised sündroomid).

Euroopa Liit - eesti - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - totsilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunosupressandid - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.